AREVIR, Kln, 08.05.2015 RESINA 2001-2014 Dr. Bjrn Jensen Klinik fr - - PowerPoint PPT Presentation

RESINA 2001-2014

• Dr. Björn Jensen

Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum Düsseldorf

AREVIR, Köln, 08.05.2015

The RESINA Study

(Genotypic HIV-Resistance in Treatment-Naives)

• Ongoing prospective study in Nordrhein-Westfalen
• Inclusion: Untreated HIV-infected subjects before ART initiation
• Study period: 2001-2014
• Aims of study:

– Epidemiology of primary resistance in chronically HIV-infected

patients

– Evaluation of efficacy of HAART guided by resistance testing – Bioinformatic analysis of resistance data – Subgroup analyses

• Classification of resistance: Shafer RW et al., Antiviral Therapy 2009
• Until end of 2014: 3811 patients (with sequence) in 36 centers
• Funding:

– Federal Ministry of Health and Social Security (BMG) – Heinz-Ansmann-Foundation for AIDS-Research

RESINA 2001-2014 Nationality w/o SSA (n=3319)

not documented 3,5% Germany 80,8% Turkey 2,4% Thailand 1,7% Russian Federation 1,4% Poland 1,1% Italy 0,9% Brazil 0,7% Greece 0,5% Spain 0,5% France 0,4% Portugal 0,4% Netherlands 0,3% Ukraine 0,3% Others (each N < 10) 5,1% not documented Germany Turkey Thailand Russian Federation Poland Italy Brazil Greece Spain France Portugal Netherlands Ukraine Others (each N < 10)

RESINA 2001-2014 Nationality only SSA(n=372)

Cameroon 16,1% Kenya 15,9% Togo 11,6% Nigeria 10,8% Ghana 10,2% Congo, Republic of (Brazzaville) 6,7% Cote d'Ivoire 3,8% Ethiopia 3,2% Sierra Leone 2,7%

• ther countries

19,1% Cameroon Kenya Togo Nigeria Ghana Congo, Republic of (Brazzaville) Cote d'Ivoire Ethiopia Sierra Leone

• ther countries

RESINA 2001-2014 Subtypes (n=2797)

B 83,1% C 1,5% 02_AG 4,4% 01_AE 3,5% A1 4,6% G 0,9%

• ther

2,1%

subtypes male patients

B C 02_AG 01_AE A1 G

• ther

RESINA 2001-2014 Subtypes (n=630)

30,3% 9,5% 18,9% 7,6% 16,0% 4,9% 12,7%

subtypes female patients

B C 02_AG 01_AE A1 G

• ther

Trends of primary HIV drug resistance: RESINA (n=3452)

0,0% 2,0% 4,0% 6,0% 8,0% 10,0% 12,0% 14,0% 16,0% 2001-2002 2003-2004 2005-2006 2007-2008 2009-2010 2011-2012 2013-2014 any NRTI NNRTI PI REVERT

Tropism: RESINA 2001-2014 (n=325)

0,0% 10,0% 20,0% 30,0% 40,0% 50,0% 60,0% 70,0% 80,0% 90,0% 100,0% 2001-2004 2005-2007 2008-2010 2011-2014 X4 X4R5 R5

Trends of HIV drug resistance: AREVIR (w/o RESINA, after ART)

10 20 30 40 50 60 70 80 90 100 %

RESINA 2001-2012 Summary

• The RESINA study provides a diverse and representative study

cohort

• TDR has to be expected in around 10% of chronically HIV-1

infected Patients

• TDR is not decreasing in this cohort despite decreasing

resistance in therapy-experienced patients;

• TDR even tends to increase overall and in the NNRTI-group

RESINA-Study Centers

Praxis Arbter, Krefeld Praxis Baumann, Neuss Praxis Becker-Boost, Duisburg Praxis Busch, Christenen, Münster Praxis Carls, Huber, Düsseldorf Praxis Dresch, Köln Uniklinik Essen, S. Esser Uniklinik Köln, G. Fätkenheuer Praxis Ferdinand, Köln Praxis Gantke, Düsseldorf Praxis Gippert, Hartmann, Quaing, Münster Praxis Grüneberg, Münster Praxis Radecki, Köln Klinikum Dortmund, M. Hower, Dortmund Praxis Isernhagen, Römer, Qurishi, Köln Praxis Knechten, Habets, Aachen Praxis Köthemann, Neuwirth, Köln Praxis Kwirant, Duisburg Praxis Mauruschat, Wuppertal Praxis Mauss, Schmutz, Hegener, Düsseldorf Praxis Miasnikov, Düsseldorf Krankenhaus der Augustinerinnen, M. Oette, Köln Klinikum Osnabrück, A. Mutz Uniklinik Düsseldorf, B. Jensen, T. Feldt, D. Häussinger Praxis Reith, Düsseldorf Klinik Kemperhof, A. Rieke, Koblenz Uniklinik Bonn, J. Rockstroh Praxis Schäfer, Bielefeld Praxis Schoelzel, Troisdorf Praxis Scholten, Köln Krankenhaus Hagen, T. Scholten, Hagen Praxis Schons, Düsseldorf Praxis Schuster, Wuppertal Praxis Stechel, Juretzko, Köln Praxis Strehlow, Petry, Düsseldorf Praxis Wiesel, Theisen, Voigt, Köln

Dieter Häussinger, Mark Oette, Stefan Reuter, Ulrike Haars, Falk Hüttig, Abdurrahman Sagir, Carola Blondin Department for Gastroenterology, Hepatology and Infectious Diseases University Hospital of Düsseldorf, Germany Rolf Kaiser, Claudia Müller, Herbert Pfister, Eugen Schülter, Melanie Balduin, Nadine Lübke, Finja Schweitzer, Jens Verheyen, Veronica di Cristanziano, Elena Knops, Angelika Hergesell Institute for Virology, University of Köln, Germany Thomas Lengauer and team, Niko Beerenwinkel Max Planck Institute for Bioinformatics, Saarbrücken